Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2015

View Archived Issues

SKY92 gene expression signature combined with ISS in MM survival prognosis

Transient expression of ZSCAN4 corrects trisomy in cells from people with Down syndrome

Homozygous mutation in PPP1R15B leads to beta-cell dysfunction and diabetes

New financing round at Pharmalink to fund development of phase III program for Nefecon

Nivolumab shows enhanced overall survival in mRCC patients

Genzyme opts into Alnylam Pharmaceuticals' ALN-AT3 hemophilia program

BioCancell advances combination of BC-819 and BCG for bladder cancer

Cellectar Biosciences awarded grant to advance phospholipid drug conjugate platform

REV-002 reduces joint pain in phase IIa trial in acute gout arthritis

DeuteRx completes financing to fund clinical trials of DRX-065 for adrenoleukodystrophy

Arvinas enters license agreement with Genentech to develop therapeutics based on PROTAC technology

Celdara and Pulmatrix receive NIH grant to develop inhaled biologic for IPF

Photocure initiates phase III study of Cysview with blue light cystoscopy in surveillance setting

New approaches for the treatment of diabetes: ECM capsules and bioactive nanocoatings

Novel mitochondrial RNA mutation linked to breast cancer

IAPs show promise for the treatment of M. tuberculosis and M. avium infections

Anthera begins phase III SOLUTION study of oral Sollpura

Encore Vision starts phase I/II trial of EV-06 in presbyopia

Algiax discloses GABA(A) receptor modulators

Bristol-Myers Squibb introduces NS5B inhibitors

Yissum reports mushroom ostreolyisin compositions

Nivalis Therapeutics divulges CFTR modulators

AstraZeneca introduces ENaC modulators

Innate Pharma initiates phase I/II trial of IPH-2201 in combination with ibrutinib for CLL

FDA approves Aristada for schizophrenia

Cardinal Health completes acquisition of J&J's Cordis business

Cobimetinib increases overall survival in patients with melanoma treated with vemurafenib

Gilead's new treatment combination of Letairis and tadalafil gains FDA approval for PAH

Cell Therapy plans European CMA submission for Heartcel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...